Filing Flows

Filing Flows › Janux Therapeutics (JANX) › Who owns the stock

Who owns Janux Therapeutics (JANX) stock

190 funds reported Janux Therapeutics (JANX) shares in their latest 13F filings, worth $1.0B in all. The largest holder is RA Capital Management, L.P. ($172M). Last quarter 108 funds added to their stakes and 70 cut them.

Largest holders of JANX (13F)Largest holders of JANX (13F)RA Capital Management, L.P.$172MBlackRock$94.2MProsight Management, LP$58.4MJanus Henderson Group$58.3MState Street$46.2MVanguard Group$40.1MFMR LLC$37.1MFederated Hermes$36.1MPoint72 Asset Management, L.P.$30.6MVanguard Capital Management LLC$28.5M

Largest holders (13F)

FundSharesValueChangeQuarter
RA Capital Management, L.P.11,189,693$172Munchanged2026-06-30
BlackRock6,134,667$94.2Mincrease2026-06-30
Prosight Management, LP3,804,481$58.4Mincrease2026-06-30
Janus Henderson Group4,196,409$58.3Mdecrease2026-03-31
State Street3,004,899$46.2Mincrease2026-06-30
Vanguard Group2,906,386$40.1Mincrease2025-12-31
FMR LLC2,412,825$37.1Mdecrease2026-06-30
Federated Hermes2,352,927$36.1Mincrease2026-06-30
Point72 Asset Management, L.P.1,993,837$30.6Mincrease2026-06-30
Vanguard Capital Management LLC1,857,351$28.5Mincrease2026-06-30
TCG Crossover Management, LLC1,789,617$27.5Munchanged2026-06-30
Alyeska Investment Group, L.P.1,647,140$25.3Mincrease2026-06-30
Nantahala Capital Management, LLC1,619,828$24.9Mincrease2026-06-30
Wellington Management Group LLP1,507,360$23.2Mdecrease2026-06-30
Vanguard Portfolio Management LLC1,330,710$20.4Mincrease2026-06-30

Janux Therapeutics' latest quarter

Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most JANX stock?

By the latest 13F filings: RA Capital Management, L.P. ($172M); BlackRock ($94.2M); Prosight Management, LP ($58.4M); Janus Henderson Group ($58.3M); State Street ($46.2M).

What is the short interest in JANX?

5,327,163 shares were sold short at the 2026-10-15 settlement, -6.28% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.